Stifel Nicolaus Sticks to Their Buy Rating for Cue Biopharma (CUE)
Express News | JMP Securities Maintains Market Outperform on Cue Biopharma, Lowers Price Target to $2
Cue Biopharma Is Maintained at Overweight by Piper Sandler
Cue Biopharma Analyst Ratings
Piper Sandler Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $3
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $2
Cue Biopharma Receives 'Buy' Rating Amid Strategic Shift and Promising Autoimmune Therapeutics Pipeline
Express News | Cue Biopharma Inc : Piper Sandler Cuts Target Price to $3 From $8
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations
Express News | Cue Biopharma Inc - Workforce Realignment Is Expected to Extend Company's Cash Runway Into Mid-Year 2025
Express News | Cue Biopharma Inc -Realigned Its Workforce Requirements Resulting in an Approximately 25% Reduction of Staff
Express News | Cue Biopharma Inc - Expects to Reduce Its Fiscal Year 2025 Operating Expenses by Approximately 25%, to a Projected Annual Cash Burn of About $30 Mln
Express News | Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $15
Express News | Cue Biopharma Presents Updated Data From Phase 1 Trial of Cue-101 in Recurrent/Metastatic Hpv+ Head and Neck Cancer at the 2024 Asco Annual Meeting
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations